An efficient new cannabinoid antiemetic in pediatric oncology

Life Sci. 1995;56(23-24):2097-102. doi: 10.1016/0024-3205(95)00194-b.

Abstract

Delta-8-tetrahydrocannabinol (delta-8-THC), a cannabinoid with lower psychotropic potency than the main Cannabis constituent, delta-9-tetrahydrocannabinol (delta-9-THC), was administered (18 mg/m2 in edible oil, p.o.) to eight children, aged 3-13 years with various hematologic cancers, treated with different antineoplastic drugs for up to 8 months. The total number of treatments with delta-8-THC so far is 480. The THC treatment started two hours before each antineoplastic treatment and was continued every 6 hrs for 24 hours. Vomiting was completely prevented. The side effects observed were negligible.

MeSH terms

  • Adolescent
  • Antiemetics / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Burkitt Lymphoma / drug therapy*
  • Child
  • Child, Preschool
  • Dronabinol / analogs & derivatives*
  • Dronabinol / therapeutic use
  • Female
  • Hodgkin Disease / drug therapy*
  • Humans
  • Infant
  • Male
  • Nausea / chemically induced
  • Nausea / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Wilms Tumor / drug therapy*

Substances

  • Antiemetics
  • delta-8-tetrahydrocannabinol
  • Dronabinol